Login to Your Account

Clinic Roundup

Thursday, July 14, 2011
Cytavis BioPharma GmbH, of Hamburg, Germany, reported that its melanoma candidate, Aviscumine (CY503), may improve survival of patients with refractory stage IV metastatic melanoma. In the Phase II open-label trial, 31 eligible patients with unresectable metastatic melanoma, who had previously failed antineoplastic therapy, received subcutaneous injections of Aviscumine. Three-month progression-free survival was 32.3 percent, and median overall survival was 11 months

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription